Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-20-070906
Filing Date
2020-06-08
Accepted
2020-06-08 17:07:44
Documents
2
Period of Report
2020-06-07

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2022027d1_4.html 4  
1 OWNERSHIP DOCUMENT tm2022027d1_4.xml 4 4526
2 EXHIBIT 99.1 tm2022027d1_ex99-1.htm EX-99.1 5247
  Complete submission text file 0001104659-20-070906.txt   11424
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT ST, SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address
Almon Einat Brill (Reporting) CIK: 0001385116 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 20949817